spacer
home > ict > Spring 2019
PUBLICATIONS

International Clinical Trials

ict
Spring 2019

   
Text
PDF
bullet
End Point
End Point

Deadly Anti-Vaxxers

ICT’s Editor, Dr Graham Hughes, discusses the worrying increase in anti-vaxxers across the US and UK, highlighting the dangers of misinformation and unsubstantiated facts.
 
view
download pdf
bullet
Features
Q&A: Clinical Trials for Glioblastoma

Impatient Patients and a New Approach to Disease Treatment

Drawing from her own experience of glioblastoma, Jessica Morris at OurBrainBank talks to about the history of her company and her aim to empower patients by giving them back control of their own disease management.
 
view
download pdf
Successful Clinical Trial Execution and Oversight
 
Efficient and Effective Vendor Management

LUMIS International’sHeike Schön and Dr Fernando Martinez explain the urgency for effective vendor management relationships for small and midsize sponsors.
 
view
download pdf
Evaluating for Market

Achieving Successful Clinical Evaluation Reports

To assess the growing complications in clinical evaluation reports, Dr Efstathios Vassiliadis at Maetrics explores the history of medical device regulations and how to keep on top of a shifting regulatory landscape.
 
view
download pdf
Achieving Growth Potential in Clinical Research
 
The CRA Gap

Dietmar Eglhofer at VIARES evaluates the alarming shortage of experienced certified research analysts, which poses a threat to the clinical research industry and is detrimental to the growth potential of CROs.
 
view
download pdf
bullet
Patient Engagement
Evaluating Clinical Trial Satisfaction Rates

Busting the Patient Engagement Myth

BBK Worldwide’s Aaron Fleishman breaks down and challenges the commonly held beliefs about patient engagement and presents the opportunities ahead for clinical trial sponsors.
 
view
download pdf
Patient Perceptions

Interpreting Patient Reported Outcomes: A Holistic Approach

Health Outcomes InsightsDr Keith Meadows presents a new approach to interpreting data from patient reported outcomes and advises on how to compensate for imperfect data.
 
view
download pdf
Patient Engagement Technology in Clinical Trials

Enhancing the Patient Experience

New technological advances should be utilised by CROs and study sponsors to improve patient satisfaction and engagement, as discussed by James Munz and Chris Watson at ERT.
 
view
download pdf
Patient Participation in Clinical Trials

Receptivity, Recruitment, and Retention

To alleviate the inherent problems with patient engagement and recruitment, Christian Burns, Joan Chambers, and Melissa Daley at ClinX push for new ways to drive ‘the three Rs’: receptivity, recruitment, and retention.
 
view
download pdf
Implementing the Patient’s Voice in Clinical Trials

The Mosaic of Patient Engagement

Patient perspectives in clinical research are a significant talking point in the development of trial design technology. Worldwide Clinical TrialsBarbara Zupancic and Dr Michael Murphy explore the value in implementing these technologies.
 
view
download pdf
A Unified Approach to Patient Engagement
 
The Perverse Incentive

Matthew McCarty at ICON establishes a greater unified approach to patient engagement, retention, and compliance through patient-facing technologies.
 
view
download pdf
bullet
Therapeutic Focus: Oncology
Precision Medicine in Modern Day Oncology

The Patient Data Paradigm

Dr Aldo Poli at OPIS examines the use of precision medicine in treating cancer and the importance of approaching clinical research from the patient’s perspective.
 
view
download pdf
bullet
eClinical Technologies
Developing a Unified eClinical Platform

E Pluribus Unum: Out of Many, One

Oracle Health SciencesCraig Morgan addresses the numerous inefficiencies in organisational siloes and how consolidation technologies may be the answer.
 
view
download pdf
Q&A: The Role of Technology in Clinical Trial Logistics

Utilising Technology on a Global Scale

Kyle Cunningham at Greenphire speaks with ICT about the use of new technologies in combatting the burdens of clinical trial research and logistics.
 
view
download pdf
bullet
Clinical Trial Insurance
Making Clinical Trial Data Accessible to Patients

A Three-Pronged Strategy

Data transparency and disclosure are a vital talking point in the wider scope of clinical trial insurance. Thomas Wicks at Trialscope discusses options for more accessible data to patients on a local and global scale.
 
view
download pdf
   
spacer


Published quarterly in
February, May,
August, and November

News and Press Releases

Turkish Cargo keeps growing steadily.

According to the international air cargo information provider WACD's September data, the global air cargo brand Turkish Cargo, which serves 126 countries of the world, grew significantly by achieving a tonnage increase of 8.8 percent in a sector wherein the global air cargo market shrank by -5.4 percent.
More info >>

White Papers

Recommendations for Implementing Assessment Criteria Guidelines in Lymphoma and Chronic Lymphocytic Leukemia Clinical Trials

Perceptive Informatics

Standardized assessment criteria are becoming increasingly important in obtaining valid outcomes in oncology clinical trials. While standardized criteria encourage a more uniform approach to assessing clinical trial data, they are often subject to the interpretation of the user. These differences in interpretation, while seemingly minor, can have a major impact on assessments. The most commonly used standardized criteria for lymphoma have been no exception. Differences such as minimum new lesion size, lymph node normalization size requirements, inclusion of extranodal lesions and assessment of organomegaly can have a profound effect on overall response. Additionally, heightened scrutiny of the assessment criteria used in a given protocol can lead to questions about a drug’s efficacy if not applied correctly according to regulators’ interpretation.
More info >>

Industry Events

ESMO Targeted Anticancer Therapies Congress 2020

2-4 March 2020, Paris, France

A unique and international mix of experts, researchers and decision makers both from academia and industry across the globe, will convene in Paris for a three-day Congress aiming at exchanging knowledge, experience and research innovations in cancer. TAT 2020 will focus, among others, on novel strategies in immuno-oncology, personalised medicine and molecular tumour boards, preclinical studies to identify effective combination therapies, use of microbiome, tumour agnostic trials, ADC technology, oncolytics, multispecific biological constructs and targeting cytokines. Participating in TAT 2020 will offer you the possibility to take part in interdisciplinary discussions inspiring new ideas and new collaborations.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement